

# Rashmi Chugh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4613973/publications.pdf>

Version: 2024-02-01

67  
papers

3,515  
citations

257450

24  
h-index

144013

57  
g-index

70  
all docs

70  
docs citations

70  
times ranked

6728  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG) Tj ETQq1.d 0.784334 rgBT	0.784334	4
2	Surgical Management of Rhabdomyosarcoma of the Nasal Cavity and Paranasal Sinuses: Analysis of Operative Indications, Settings, and Outcomes. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, 350-358.	0.8	2
3	Factors associated with disease-free and abdominal recurrence-free survival in abdominopelvic and retroperitoneal sarcomas. Journal of Surgical Oncology, 2022, 125, 1292-1300.	1.7	5
4	Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications. Oncologist, 2022, 27, 595-599.	3.7	9
5	SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. Cancer, 2021, 127, 1301-1310.	4.1	20
6	Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. Cancer, 2021, 127, 1311-1317.	4.1	8
7	Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors. JAMA Oncology, 2021, 7, 525-533.	7.1	65
8	Breast Sarcomas, Phyllodes Tumors, and Desmoid Tumors: Epidemiology, Diagnosis, Staging, and Histology-Specific Management Considerations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 390-404.	3.8	12
9	Psychosocial, behavioral, and supportive interventions for pediatric, adolescent, and young adult cancer survivors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 160, 103291.	4.4	31
10	Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).. Journal of Clinical Oncology, 2021, 39, 11563-11563.	1.6	2
11	Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART). , 2021, 9, e002990.		58
12	Sunitinib for Patients With Malignant Perivascular Epithelioid Cell Tumors. Journal of Clinical Oncology, 2021, 39, 3660-3670.	1.6	69
13	Current clinical management of primary cardiac sarcoma. Expert Review of Anticancer Therapy, 2020, 20, 45-51.	2.4	23
14	Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sunitinib in Combination with Ganetespib (SARC023). Sarcoma, 2020, 2020, 1-8.	1.3	33
15	A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. Investigational New Drugs, 2020, 38, 1421-1429.	2.6	33
16	Wnt/ $\beta$ -catenin-activated Ewing sarcoma cells promote the angiogenic switch. JCI Insight, 2020, 5, .	5.0	21
17	Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Sarcoma, 2019, 2019, 1-8.	1.3	45
18	A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer, 2019, 125, 2445-2454.	4.1	19

#	ARTICLE	IF	CITATIONS
19	Primary Cardiac Sarcoma: A Rare, Aggressive Malignancy with a High Propensity for Brain Metastases. <i>Sarcoma</i> , 2019, 2019, 1-6.	1.3	31
20	Successful embryo cryopreservation immediately following a full-term delivery in a woman with newly diagnosed Ewing's sarcoma. <i>Journal of Assisted Reproduction and Genetics</i> , 2019, 36, 1023-1028.	2.5	2
21	Differential Outcomes and Biologic Markers of Radiation-Associated vs. Sporadic Osteosarcoma: A Single-Institution Experience. <i>Frontiers in Oncology</i> , 2019, 9, 1523.	2.8	6
22	Pilot study investigating an oncofertility program in adults with breast or sarcoma cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, e23096-e23096.	1.6	0
23	Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. <i>JAMA Oncology</i> , 2018, 4, 814.	7.1	26
24	Canonical Wnt/ $\beta$ -catenin signaling activation in soft-tissue sarcomas: A comparative study of synovial sarcoma and leiomyosarcoma. <i>Rare Tumors</i> , 2018, 10, 203636131881343.	0.6	8
25	Systemic Therapies for Locally Recurrent or Metastatic Disease. , 2018, , 399-409.		0
26	SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. <i>Sarcoma</i> , 2018, 2018, 1-9.	1.3	13
27	Mutational analysis and safety/efficacy in a phase 2 multi-center investigation of ABI-009 (nab-papamycin) in patients with advanced malignant perivascular epithelioid cell tumors (PEComa).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS11589-TPS11589.	1.6	0
28	Inferior vena cava leiomyosarcoma: A single-institution experience.. <i>Journal of Clinical Oncology</i> , 2018, 36, e23556-e23556.	1.6	0
29	Prevalence of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among newly diagnosed cancer patients treated in academic and community oncology practices: SWOG S1204.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6600-6600.	1.6	0
30	A comparison of outcomes, presentation, and treatment in pediatric (Ped) versus adult patients (Pts) with Ewing sarcoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11528-11528.	1.6	0
31	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. <i>Cancer Discovery</i> , 2017, 7, 620-629.	9.4	321
32	Integrative clinical genomics of metastatic cancer. <i>Nature</i> , 2017, 548, 297-303.	27.8	685
33	Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. <i>Cancer</i> , 2017, 123, 90-97.	4.1	101
34	The potential of emerging therapeutics for epithelioid sarcoma. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 983-989.	0.8	2
35	Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. <i>Oncotarget</i> , 2017, 8, 89848-89866.	1.8	45
36	Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 3579-3587.	4.3	4

#	ARTICLE	IF	CITATIONS
37	Clinical application of comprehensive next generation sequencing in the management of metastatic cancer in adults.. Journal of Clinical Oncology, 2017, 35, 101-101.	1.6	7
38	Next generation sequencing of extraskeletal myxoid chondrosarcoma. Oncotarget, 2017, 8, 21770-21777.	1.8	20
39	Radiation-associated versus sporadic osteosarcoma: A single-institution experience.. Journal of Clinical Oncology, 2017, 35, 11018-11018.	1.6	0
40	SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer, 2016, 122, 868-874.	4.1	80
41	Activation of Wnt/ $\beta$ -Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States. Cancer Research, 2016, 76, 5040-5053.	0.9	70
42	Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. Journal of Clinical Oncology, 2016, 34, 3680-3685.	1.6	17
43	SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy. BMC Cancer, 2016, 16, 663.	2.6	2
44	Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 2500-2500.	1.6	14
45	A bivalent promoter contributes to stress-induced plasticity of CXCR4 in Ewing sarcoma. Oncotarget, 2016, 7, 61775-61788.	1.8	16
46	Aldoxorubicin in Sarcoma. JAMA Oncology, 2015, 1, 1280.	7.1	2
47	A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. European Journal of Cancer, 2015, 51, 1794-1802.	2.8	29
48	The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Research, 2015, 25, 1372-1381.	5.5	139
49	A retrospective analysis of patients with soft tissue sarcoma treated long-term with trabectedin.. Journal of Clinical Oncology, 2015, 33, 10551-10551.	1.6	1
50	Clinical impact of high-throughput sequencing in patients with advanced cancer: Lessons learned from the Michigan Oncology Sequencing Center.. Journal of Clinical Oncology, 2015, 33, 11057-11057.	1.6	2
51	ATR-101 phase 1 clinical study for adrenocortical carcinoma.. Journal of Clinical Oncology, 2015, 33, TPS4585-TPS4585.	1.6	3
52	The who and what of imaging in sarcoma and correlation with survival.. Journal of Clinical Oncology, 2015, 33, 10511-10511.	1.6	0
53	Diffuse Hypopigmentation Followed by Hyperpigmentation in an African American Woman with Hemangiopericytoma Treated with Dasatinib. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, QD01-2.	0.8	5
54	A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.. Journal of Clinical Oncology, 2014, 32, 2528-2528.	1.6	42

#	ARTICLE	IF	CITATIONS
55	Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.. Journal of Clinical Oncology, 2014, 32, 7522-7522.	1.6	22
56	Late relapse in soft tissue sarcoma: Prognostic factors for recurrence after 3 years.. Journal of Clinical Oncology, 2014, 32, 10570-10570.	1.6	0
57	Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. European Journal of Cancer, 2012, 48, 1347-1353.	2.8	50
58	R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study. Journal of Clinical Oncology, 2011, 29, 4541-4547.	1.6	293
59	Experimental Therapies and Clinical Trials in Bone Sarcoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 715-725.	4.9	5
60	Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial. Clinical Cancer Research, 2010, 16, 4884-4891.	7.0	213
61	Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model. Journal of Clinical Oncology, 2009, 27, 3148-3153.	1.6	210
62	Pharmacotherapy of sarcoma. Expert Opinion on Pharmacotherapy, 2009, 10, 1953-1963.	1.8	4
63	Chordoma: The Nonsarcoma Primary Bone Tumor. Oncologist, 2007, 12, 1344-1350.	3.7	342
64	Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. Cancer, 2007, 109, 2315-2322.	4.1	18
65	Randomized Phase II Evaluation of 6 g/m2 of Ifosfamide Plus Doxorubicin and Granulocyte Colony-Stimulating Factor (G-CSF) Compared With 12 g/m2 of Ifosfamide Plus Doxorubicin and G-CSF in the Treatment of Poor-Prognosis Soft Tissue Sarcoma. Journal of Clinical Oncology, 2005, 23, 105-112.	1.6	65
66	Phase II Study of 9-Nitro-Camptothecin in Patients With Advanced Chordoma or Soft Tissue Sarcoma. Journal of Clinical Oncology, 2005, 23, 3597-3604.	1.6	87
67	Nonepithelial malignancies of the breast. Oncology, 2004, 18, 665-73; discussion 673-6.	0.5	11